Replimune stock surged approximately 131% to near $12.50 ahead of Friday’s regular trading. A panel of FDA advisers voted 10-3 in favor of RP1’s IGNYTE efficacy data being interpretable and clinically important.
The decision countered the regulatory setback earlier in the week. FDA staff had raised concerns over the study’s setup and how responses were measured. The final ruling is expected on Sunday, August 2.
The market gained close to $596 million in basic equity value, based on an estimated 84.03 million shares outstanding. The initial figure does not factor in warrants or potential future dilution.
Market adjusts values ahead of FDA ruling
Metric
Thursday close
Friday premarket
Change
Share price
$5.41
$12.50
up 131.1%
Basic equity value
$454.6 million
$1.050 billion
increase of $595.8 million
Enterprise value
$269.0 million
$864.8 million
gain of $595.8 million
Initial figures are based on 84.03 million shares and the most recent premarket quote. Enterprise value factors in $268.9 million in cash and investments as of March 31, with $83.3 million in debt. Cash used and dilution after this period are not included.
Enterprise value provides a clearer indicator. It increased by 3.2 times following the adjustment for net cash in March. Replimune has not reported any product sales to date.
BMO Financial Group’s NYSE:BMO Evan Seigerman described the testimony as having “made a compelling case for RP1 despite FDA criticism.” He stated that accelerated approval is “almost certain.” Wedbush lifted its price target to $12, which remains under the premarket level. Reuters
The effectiveness headline mirrors that of the authorised U.S. counterpart, but the delivery requirements are different.
RP1 and the standard benchmark for approved melanoma treatments
Metric
RP1 plus Opdivo
Amtagvi
Companies
Replimune; Opdivo from Bristol Myers Squibb NYSE:BMY
Tumour removal, product creation, hospital conditioning, and IL-2
Safety marker
No treatment-related Grade 5 reports per sponsor
Regimen starters saw 7.5% treatment-related death rate
This is not a direct comparison. RP1 data are provided by the sponsor, and FDA reviewers question how these results should be interpreted. Data and treatment criteria for Amtagvi are sourced from its FDA label.
Cross-trial comparisons are not sufficient to prove superiority, but they influenced the panel’s discussion on practical matters. Melanoma expert Hussein Tawbi described RP1 as “a lot safer, a lot easier” compared to Amtagvi. Reuters
FDA reviewers were not convinced about efficacy, stating that response criteria artificially increased reported results. The added effect of RP1 alongside nivolumab was not shown.
The study, conducted without a control arm, lacked a comparator group. Reviewers described the median overall survival of 32.9 months as uninterpretable. Significant uncertainty persists.
Replimune’s randomised IGNYTE-3 study is ongoing. The sponsor projects overall-survival data in 2030. This means any accelerated launch would come before the data readout.
Cash is still the second key test. Outlays increased rapidly ahead of the regulatory ruling.
Financial strain during the fiscal year
Metric, year ended March 31
FY2025
FY2026
Change
Research and development
$189.4 million
$221.2 million
+17%
Selling, general and administrative
$72.2 million
$98.7 million
+37%
Net loss
$247.3 million
$313.9 million
+27%
Operating cash use
$192.3 million
$280.3 million
+46%
Cash and short-term investments
$483.8 million
$268.9 million
-44%
Data come from Replimune’s annual report for fiscal 2026. The firm recorded zero product sales.
The March balance supported operations through early 2027, not accounting for product revenue in the projection. If approved, the term-loan maturity would be pushed back from October 2027 to October 2029.
Simple valuation calculations overlook possible dilution as well. As of March, Replimune reported 14.1 million pre-funded warrants outstanding. At Friday’s premarket price, these were worth approximately $176 million.
CEO Sushil Patel stated, “We look forward to continuing to work with the FDA.” Investors are now waiting for the regulator’s decision. Reuters
Immediate risk is binary. The FDA could still deny RP1 even after the positive vote. Regulatory clearance may include stringent post-marketing obligations. High cash outflow, potential dilution, or failure in confirmatory studies may erase much of Friday’s surge.
TS2 TECH • EXTENDED COVERAGE
Further analysis
Editorial insight
What is driving Replimune shares higher today?
REPL finished Thursday at $5.41 and was trading close to $12.56 in Friday's premarket, up about 132% ahead of the opening bell. The move followed a 10-3 FDA advisory panel vote backing RP1. The committee determined IGNYTE’s efficacy findings were both evaluable and clinically significant. Shares began Friday having lost 44% year to date, making the rebound notable. Barron's
Does a 10-3 advisory vote guarantee that the FDA will grant approval?
Approval remains uncertain. Advisory committee recommendations are not binding, with the FDA’s decision expected by August 2, 2026. FDA staff also raised concerns over response metrics, the role of specific components, and how overall survival was interpreted. According to reports, a BMO analyst described approval as almost guaranteed following Thursday’s result. This perspective reflects only that analyst's view. Investors should continue to consider the outcome a binary regulatory risk. The Wall Street Journal
What were the precise findings of the IGNYTE trial?
Among 140 melanoma patients whose disease had progressed on anti-PD-1 therapy, the objective response rate was 33.6%. Responders saw a median duration of response of 24.8 months. The 95% confidence interval for the response rate ranged from 25.8% to 42.0%. Data from the sponsor indicated a 47.8% overall survival rate at three years. Most toxicities were grade 1 or 2; no grade-five adverse events were observed. The FDA questioned whether the single-arm study design can definitively establish RP1’s effect. Replimune Group Inc.
What were the reasons for the FDA to reject RP1 on two occasions prior to this decision?
The FDA sent complete response letters on July 22, 2025, and April 10, 2026, both raising concerns over whether IGNYTE could demonstrate efficacy in the absence of a control arm. Staff noted that some tumor responses seen could possibly be due to nivolumab alone. Reviewers further said that response criteria might inflate reports of tumor shrinkage. Replimune maintains that previous communications with the agency indicated support for its accelerated-approval strategy. The disagreement is still unresolved, even after Thursday’s supportive advisory panel vote. Applied Clinical Trials
What follows once accelerated approval is granted?
A green light would mark Replimune’s debut commercial product and its initial shot at revenue. The pivotal Phase 3 IGNYTE-3 trial is enrolling around 400 participants as a confirmatory study. Overall survival is set as the main outcome, with progression-free survival and response as secondary measures. The protocol outlines two years of therapy followed by three years of monitoring. The process of confirmation will extend over several years. The company’s stock will be influenced by commercial rollout, reimbursement, and the scope of the drug’s label. SEC
How are analysts projecting the outcome after the panel's decision?
Wedbush raised REPL to Outperform and increased its price target to $12. Cantor shifted the rating to Overweight, while the latest targets from BMO and JPMorgan were $16 and $17 respectively. The consensus on price targets remains widely spread. One feed made up of six analysts posts an average target of $10.67, ranging from $2 to $17. Separately, a seven-analyst feed shows an average of just $8.71. REPL traded at $12.56 premarket, already topping several listed averages. Numerous targets were set before Thursday’s vote and could be revised shortly. investing.com
What is an expected short-term price range following the FDA decision?
An indicative event-driven range is estimated between $5 and $17. The lower bound reflects Thursday’s regular session close at $5.41, while the upper bound is set by the highest analyst target currently available. Regulatory approval could maintain the present revaluation, though specifics of the label would determine additional gains. A rejection could undo a substantial part of the premarket rise. This scenario frame is not a weighted forecast. Barron's
Is Replimune able to support its operations and fund a launch for RP1?
As of March 31, cash and short-term investments stood at $268.9 million, while long-term debt was about $83.3 million. The net loss for fiscal 2026 totaled $313.9 million. Management indicates current cash is expected to extend into the first quarter of 2027, not factoring in any possible revenue. Replimune reduced its workforce by roughly 55% in April; details on the post-reduction cash burn rate have not been disclosed. The ATM facility held $67.9 million available, with 14.06 million pre-funded warrants outstanding. Financing and dilution risks continue to be significant. Replimune Group Inc.
Are there any additional pipeline assets after RP1 for melanoma?
RP2’s REVEAL trial aims to enroll about 280 patients with metastatic uveal melanoma. The study will evaluate RP2 with nivolumab versus a combination of ipilimumab and nivolumab. The phase 2/3 progression is planned for the first quarter of 2027. An earlier cohort of 17 patients achieved a 29.4% objective response rate. Initial data in hepatocellular carcinoma are expected before the end of 2026. These developments offer additional opportunities, but they do not currently offset near-term binary risk tied to RP1. Replimune Group Inc.
Are biotechnology indexes responsible for today’s movement?
No, this development is unique to the company. The Nasdaq Biotechnology Index rose 0.78% on Thursday and is up 15.15% so far this year. REPL began Friday at a 44% decline for 2026, before surging about 132% in premarket trade. This divergence far surpasses usual daily shifts in biotech indexes. Today's move is being driven by RP1’s regulatory decision, not wider biotechnology sector trends. marketwatch.com
Marcin Frąckiewicz is the founder and CEO of TS2 Space, a satellite communications company serving customers around the world. A graduate of the Warsaw School of Economics (SGH), he has more than two decades of experience in telecommunications, satellite services and technology ventures. He writes about satellite communications, space technology, artificial intelligence and the stock market, with a particular focus on technology companies, semiconductors, emerging industries and the trends shaping global innovation. Follow Marcin Frąckiewicz on Google News, Facebook. or Linkedin.
